Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

Background: A liposomal formulation of eribulin, E7389-LF, may provide improved pharmacokinetics and allow increased access to tumour tissues. This expansion of a phase 1 study assessed the safety and efficacy of E7389-LF in patients with human epidermal growth factor receptor type 2-negative metast...

Full description

Bibliographic Details
Main Authors: Harano, K. (Author), Kobayashi, K. (Author), Kogawa, T. (Author), Masuda, N. (Author), Mizutani, M. (Author), Mukohara, T. (Author), Nagai, R. (Author), Okumura, S. (Author), Ono, M. (Author), Ren, M. (Author), Semba, T. (Author), Shimoi, T. (Author), Suzuki, T. (Author), Takahashi, S. (Author), Takase, T. (Author), Tanioka, M. (Author), Yasojima, H. (Author), Yonemori, K. (Author), Zhao, Z.-M (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
Breast cancer
Eribulin
Liposomal
Neutropenia
Phase 1
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items